NCT05252338 - A Study to Evaluate the Safety, Reactogenicity and Immunogenicity of Vaccine CVSQIV in Healthy Adults | Biotech Hunter

Enrollment

240

Participants

Timeline

Start Date

February 7, 2022

Primary Completion Date

September 27, 2022

Study Completion Date

September 27, 2022

Conditions

Influenza

Interventions

BIOLOGICAL

CVSQIV

Participants will receive an intramuscular injection by needle in the deltoid area.

Trial Locations (3)

International Vaccination and Research Center (CEVAXIN) Avenida Mexico, 33 Street, Panama City

International Vaccination and Research Center (CEVAXIN) Panama Clinic, Ramon H Jurado Street, Pacific Center, Level 12, Panama City

Unidad de Investigación Clínica INDICASAT AIP / Hospital Paitilla, Panama City